-
Innovation Ranking
Innovation Ranking – Fulcrum Therapeutics Inc
Fulcrum Therapeutics Inc (Fulcrum Therapeutics) is a drug development company. The company is involved in the discovery and development of small molecule therapies to unlock gene regulation in diseases. Its pipeline products include losmapimod for treating facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058 for treating sickle cell disease and β Thalassemia. The company also owns a proprietary product engine FulcrumSeek, which detects drug targets that can control gene expression and treat the root cause of gene misexpression. The company’s key therapeutic...
-
Company Insights
Innovation and Patenting activity of Fulcrum Therapeutics Inc Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Fulcrum Therapeutics Inc Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewFacioscapulohumeral Muscular Dystrophy (FSHD) – Drugs In Development, 2024
Empower your strategies with our Facioscapulohumeral Muscular Dystrophy (FSHD) – Drugs In Development, 2024 report and make more profitable business decisions. Facioscapulohumeral muscular dystrophy (FSHD) typically manifests with varying degrees of facial, scapular stabilizer, and dorsiflexor muscle weakness. Progression is slow, with about 20% of individuals eventually requiring a wheelchair, though life expectancy remains unaffected. Diagnosis of FSHD1 involves identifying a heterozygous pathogenic contraction of the D4Z4 repeat array on chromosome 4q35 with a chromosome 4 permissive haplotype. FSHD2 diagnosis is...
-
Product Insights
NewMyotonic Dystrophy – Drugs In Development, 2024
Empower your strategies with our Myotonic Dystrophy – Drugs In Development, 2024 report and make more profitable business decisions. Myotonic dystrophy (DM), also known as dystrophia myotonica, is a group of genetic disorders characterized by progressive muscle weakness, myotonia (delayed relaxation of muscles after contraction), and various multi-systemic manifestations. It is one of the most common forms of adult-onset muscular dystrophy and can affect multiple organs and systems in the body. There are two main types of myotonic dystrophy, DM1 and...
-
Product Insights
NewFriedreich Ataxia – Drugs In Development, 2024
Empower your strategies with our Friedreich Ataxia – Drugs In Development, 2024 report and make more profitable business decisions. Friedreich’s ataxia (FA) is a neuromuscular disease that mainly affects the nervous system and the heart. FA is a hereditary disease, caused by a defective gene that can be passed down through a family. Signs and symptoms include ataxia, weakness and spasticity, sensory impairment, skeletal abnormalities, cardiac difficulties, and diabetes. The Friedreich Ataxia drugs in development market research report provide comprehensive information...
-
Product Insights
NewMuscular Dystrophy – Drugs In Development, 2024
Empower your strategies with our Muscular Dystrophy – Drugs In Development, 2024 report and make more profitable business decisions. Muscular dystrophy is a group of diseases in which muscle fibers are unusually susceptible to damage. These damaged muscles become progressively weaker. Symptoms usually appear before age 6 and may appear as early as infancy. They may include fatigue, learning difficulties, intellectual disability, muscle weakness, and progressive difficulty walking. The Muscular Dystrophy drugs in development market research report provide comprehensive information on...
-
Product Insights
NewSickle Cell Disease – Drugs In Development, 2024
Empower your strategies with our Sickle Cell Disease – Drugs In Development, 2024 report and make more profitable business decisions. Sickle cell anemia is a genetic (inherited) blood disorder in which red blood cells, which carry oxygen around the body, develop abnormally. Signs and symptoms include anemia, delayed growth, vision problems, pain and frequent infections. Treatment includes antibiotics, pain relievers, blood transfusion and stem cell transplant. The Sickle Cell Disease drugs in development market research report provide comprehensive information on the...
-
Product Insights
NewDuchenne Muscular Dystrophy – Drugs In Development, 2024
Empower your strategies with our Duchenne Muscular Dystrophy – Drugs In Development, 2024 report and make more profitable business decisions. Duchenne muscular dystrophy (DMD) is a genetic disorder that causes muscles to gradually weaken over time. Signs and symptoms of DMD include fatigue, learning difficulties, intellectual disability, muscle weakness, and progressive difficulty walking. Risk factors include gender and family history. Treatments include steroid medication, respiratory therapy, and surgery. The Duchenne Muscular Dystrophy drugs in development market research report provide comprehensive information...
-
Product Insights
Electrophysiology Ablation Catheters Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Electrophysiology Ablation Catheters Pipeline Market Report Overview Electrophysiology ablation is applicable for a wide variety of arrhythmias and has an extremely high success rate with low rates of complication and recurrence. The electrophysiology ablation catheters pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and...
-
Product Insights
NewRecessive X Chromosome Disorders – Drugs In Development, 2024
Empower your strategies with our Recessive X Chromosome Disorders – Drugs In Development, 2024 report and make more profitable business decisions. A recessive X chromosome disorder, also known as an X-linked recessive disorder, is a genetic condition caused by a mutation on one of the X chromosomes, one of the two sex chromosomes. Typically, males have one X and one Y chromosome (XY), while females have two X chromosomes (XX). In recessive X-linked disorders, the mutated gene is located on the...